The global near-infrared imaging market was valued at USD 2.24 billion in 2024 and is anticipated to reach USD 3.52 billion by 2035. This represents a compound annual growth rate (CAGR) of 4.20% during the forecast period from 2025 to 2035.
Global Near Infrared Imaging Market Size, Trend & Opportunity Analysis Report, by Product (Devices (Near-infrared Fluorescence Imaging Systems, Near-infrared Fluorescence & Bioluminescence Imaging Systems), Reagents (Indocyanine Green (ICG), Other Reagents)), Indication (Preclinical Imaging, Cancer Surgeries, Gastrointestinal Surgeries, Cardiovascular Surgeries, Plastic/Reconstructive Surgeries, Other Applications), End Use (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Research Laboratories), and Forecast, 2025-2035
Report Code: LSMD528Author Name: Dhwani SharmaPublication Date: October 2025Pages: 290
Available In:
Global Near Infrared Imaging Market Size, Opportunity Analysis and Forecast, 2025-2035
Publication Date: Oct 22, 2025Pages: 290
Near Infrared Imaging Market Definition and Introduction
The Global Near-Infrared Imaging Market was valued at USD 2.33 Billion in 2025 and is anticipated to reach USD 3.67 billion by 2035, expanding at a CAGR of 4.65% during the forecast period 2025-2035. As the precision medicine approach to diagnosis and treatment, combined with the recent advances in surgery and the strong demand for early diagnostics, reshapes the medical imaging industry, near infrared (NIR) imaging stands at the forefront of this evolution. Increasingly, hospitals, research laboratories, and pharmaceutical companies are finding value in NIR techniques for real-time visualisations, minimally invasive surgeries, and targeted imaging, thereby creating a demand for devices and reagents. At the same time, the push for personalised medicine is strengthening the place of molecular imaging platforms, where NIR fluorescence guidance has become crucial for accurate tumour margin detection and preclinical studies.
Key Market Trends & Analysis
- Near Infrared Imaging Market reached USD 2.33 Billion in 2025, supported by rising precision medicine and advanced surgical imaging demand.
- The market is projected to expand at a 4.65% CAGR from 2025 to 2035, indicating steady industry growth.
- Near Infrared Imaging Market is anticipated to reach USD 3.67 Billion by 2035, driven by oncology and preclinical applications.
- Rising oncology procedures and precision medicine adoption are accelerating NIR imaging demand for fluorescence-guided surgery and targeted diagnostics.
- Devices hold the largest market share, driven by intraoperative guidance, diagnostic accuracy, and integration into advanced surgical platforms.
- Cancer surgeries dominate indication segmentation as fluorescence guidance supports tumour margin detection and minimally invasive oncological procedures.
- Reagents represent a fast-growing segment, supported by translational research, drug validation, and expanding applications beyond oncology.
- North America dominates regional market adoption, supported by advanced oncology infrastructure, regulatory approvals, clinical research, and leading manufacturers.
- Asia-Pacific records the highest regional growth, driven by healthcare expansion, rising cancer patients, and increasing government investments.
- Stryker Corporation launched advanced near-infrared fluorescence systems in March 2024, enhancing precision and integration within oncological operating room workflows.
Near Infrared Imaging Market Size and Growth Projection:
- Market Size in 2025: USD 2.33 Billion
- Market Size by 2035: USD 3.67 Billion
- CAGR: 4.65% from 2025 to 2035
- Base Year: 2025
- Forecast Period: 2025–2035
- Historical Data: 2022–2024
Thus, the stakeholders of the regulatory and healthcare policies are now nudging the industry to embrace technologies that promise reduced surgical risks, faster patient recovery, and reproducibility of data. The rise in investments flowing into cancer-related research, together with the global increase in oncology procedures, has made it more accelerated for NIR imaging to establish itself in clinical workflows. Surgeons utilise intraoperative imaging tools for better decision-making, and pharmaceutical companies leverage NIR reagents to validate pathways of drug delivery. This wider scope is making the market versatile and increasingly commercially attractive.
On the supply side, device manufacturers and reagent developers are strengthening their partnerships with hospitals and academic institutions to design next-generation imaging systems. The compulsion to optimise accuracy while lowering costs has catalysed innovations in detector sensitivity, probe development, and compact imaging systems for both clinical and research applications. In addition, the emergence of hybrid imaging systems combining NIR with MRI and PET has opened new avenues for commercialisation, thus paving the way for robust growth throughout the forecast period.
Recent Developments in the Near Infrared Imaging Industry
- In March 2024, Stryker Corporation extended its surgical imaging lineup with the launch of advanced near-infrared fluorescence systems, seamlessly integrated into operating room workflows to increase precision in oncological surgeries.
- In June 2024, the fluorescence imaging platform for gastrointestinal and liver surgeries, which would facilitate intraoperative tumour visualisation with advanced NIR technology, was launched by Olympus Corporation.
- In February 2025, PerkinElmer Inc. launched a new line of near-infrared fluorescent probes to be used for translational oncology studies, designed to connect preclinical and clinical applications in imaging.
- In April 2023, Hamamatsu Photonics K.K. launched a next-generation photodetector with greater sensitivity in NIR applications, increasing image resolution in small-animal preclinical studies.
- In October 2024, Medtronic plc announced its funding effort to develop integrated NIR fluorescence systems for minimally invasive oncology procedures to facilitate precision surgery with low recurrence.
Near Infrared Imaging Market Dynamics: Drivers, Restraints, Opportunities, Challenges and Trends
NIR Imaging Market Growth Accelerates Through Precision Medicine and Rising Adoption in Oncological Surgery.
The continued proliferation of oncology surgeries worldwide has solidified the role of NIR imaging as a key player in tumour detection and resection. Fluorescence-guided procedures used by surgeons are enhancing surgical outcomes, while hospitals increasingly integrate these devices within surgical suites. Disturbingly, this trend is further amplified by the rapidly accelerating pace of precision medicine, whose unique therapies require advanced imaging platforms for targeted drug delivery verification.
Hybrid NIR Imaging Technologies Accelerate Market Growth Through Integration With MRI, PET, and Multiparametric Imaging.
The fusion of NIR imaging with complementary modalities such as MRI and PET is ushering in the establishment of next-generation hybrid systems with multiparametric insights. At the same time, the development of highly specific NIR reagents has broadened applications from oncology to the fields of cardiovascular research, neuroscience, and drug discovery in preclinical studies. These trends are widening the spectrum of applicability for practices beyond oncology.
Stringent Regulatory Frameworks Shape NIR Imaging Market Growth Through Enhanced Clinical Safety and Standardisation.
Stringent regulatory guidelines, especially across Europe and North America, are ensuring the standardisation of imaging quality and safety in the clinical setting. Although such frameworks run to bolster trust and adoption, on the contrary, they raise manufacturers' compliance costs and demand continuous updating of product validation and certification processes. The competitive advantage remains for those companies that can find an equilibrium between regulation, cost, and technology.
High Capital Costs Constrain NIR Imaging Market Adoption Across Budget-Sensitive Hospitals and Emerging Healthcare Markets.
Despite its clinical advantages, the capital-intensive NIR imaging systems require substantial investment in both equipment and training. This constitutes an obstacle to adoption for smaller hospitals and facilities in emerging economies, leading to inequalities in accessibility. However, this problem is being levelled out, gradually, with the arrival of many portable and affordable imaging systems into the market.
Preclinical Research Accelerates NIR Imaging Market Growth Through Rising Pharmaceutical and Biotechnology Investments.
Pharmaceutical and biotech companies scale their investments in NIR-based translational research for validating molecular therapies, which
in turn drives up the demand for reagents and imaging platforms designed for laboratory use. With drug pipelines becoming more and more convoluted, NIR imaging is providing a non-invasive and reproducible method of visualising therapeutic efficacy, creating lucrative commercial opportunities for the developers of reagents and manufacturers of devices.
Where Are the Biggest Opportunities in the Near Infrared Imaging Market?
- Fluorescence-Guided Surgery Growth - Expanding role of NIR imaging in tumour margin detection accelerates adoption.
- Hybrid Imaging Systems Demand - Integration with MRI and PET modalities unlocks multiparametric diagnostic possibilities.
- Reagent Innovation Pipeline - Development of disease-specific NIR probes drives translational and clinical research growth.
- Preclinical Research Expansion - Rising drug discovery studies enhance demand for laboratory NIR imaging solutions.
- Portable Imaging Solutions - Compact, cost-effective devices boost accessibility across emerging economies.
- Regulatory Endorsement Benefits - Positive approvals and guidelines improve physician trust and clinical acceptance.
- Oncology Procedure Surge - Rising cancer burden globally reinforces demand for NIR-guided surgeries.
- Collaborative R&D Platforms - Academia-industry partnerships fast-track innovation in devices and reagents.
- Digital Workflow Integration - Seamless data integration enhances hospital adoption and decision-making accuracy.
- Asia-Pacific Market Expansion - Regional manufacturing and healthcare growth spur NIR device and reagent uptake.
Near Infrared Imaging Market Segmentation Analysis
Report Attributes | Details |
Market Size in 2025 | USD 2.33 Billion |
Market Size by 2035 | USD 3.67 Billion |
CAGR (2026-2035) | 4.65% |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Historical Data | 2022-2024 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, Analysis, Forecast Outlook |
Key Segments | By Product:Devices (Near-infrared Fluorescence Imaging Systems, Near-infrared Fluorescence & Bioluminescence Imaging Systems) Reagents (Indocyanine Green (ICG), Other Reagents) By Indication: Preclinical Imaging, Cancer Surgeries, Gastrointestinal Surgeries, Cardiovascular Surgeries, Plastic/Reconstructive Surgeries, Other Applications By End Use: Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Research Laboratories |
Regional Analysis/Coverage | North America (U.S, Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, rest of Asia Pacific), LAMEA (Latin America, Middle East, and Africa) |
Company Profiles | Stryker Corporation, Olympus Corporation, Karl Storz SE & Co. KG, PerkinElmer Inc., Hamamatsu Photonics K.K., Leica Microsystems, Quest Medical Imaging, Medtronic plc, Shimadzu Corporation, and LI-COR Biosciences. |
Near Infrared Imaging Market: Dominating Segments
NIR Imaging Devices Dominate Market Share Through Rising Adoption in Surgery, Diagnostics, and Clinical Research.
Devices have the greatest share in the NIR imaging market due to their unquestionable role in intraoperative guidance and diagnostic accuracy. Fluorescence-enabled imaging devices are now more widely adopted in hospitals and surgical centres due to the need for improved accuracy in oncological interventions requiring identification of tumour margins. Additionally, features of NIR modules are being incorporated into surgical platforms by device manufacturers, thereby enhancing their usefulness across various specialities. Demand for advanced, versatile devices continues to grow with the increasing acceptance of hybrid imaging systems.
NIR Imaging Reagents Accelerate Market Growth Through Rising Translational Research and Precision Diagnostics Adoption.
Currently, the reagents are amongst the fastest-growing segments for NIRs as research institutions and pharmaceutical companies intensify efforts in drug validation and imaging-aimed applications. These reagents aid in visualising biological processes, tracking disease development, and ultimately assessing drug efficacy. Rising cancer-related studies and advances in probe specificity guarantee a constant growth in demand. With applications extending beyond oncology towards neurology and cardiovascular research, the reagents are unlocking new revenue opportunities.
Cancer Surgeries Lead NIR Imaging Market Adoption Through Fluorescence-Guided Tumour Resection and Precision Oncology.
Cancer surgeries are the prime indication for NIR imaging since surgeons exploit fluorescence guidance to confirm complete tumour resection, envisaging minimal impact on healthy tissues. The rising prevalence of malignant pathologies worldwide, along with requirements for minimally invasive surgical intervention, strengthens this segment. Government measures to improve cancer care infrastructure will further substantiate adoption, thereby allowing NIR imaging to take a well-deserved place within the infrastructure for oncology procedures.
Preclinical Imaging Accelerates NIR Imaging Market Growth Through Rising Pharmaceutical and Biotechnology Research Investments.
Preclinical imaging is emerging as a crucial section, especially in drug discovery and translational studies. NIR is used to visualise biological processes in small animals, therefore improving reproducibility and accelerating the validation of therapy. With the unprecedented increase in funding within biotechnology, coupled with the intricate nature of modern drug pipelines, NIR imaging has become a respected technique for non-invasive research, thereby ensuring steady growth of the segment.
Regional Insights in the Near Infrared Imaging Market
North America Leads NIR Imaging Market Through Advanced Oncology Infrastructure and Strong Regulatory Support.
The United States accounts for most of the regional market, thanks to its well-developed oncology infrastructure, advanced acceptance of surgical innovations, and the strength of leading manufacturers in the industry. Adoption is further boosted by the high numbers of stringent FDA approvals and the increased pace of clinical research in cancer care, while Canadian and Mexican health systems are extending funding into new advanced imaging platforms.
Europe Strengthens NIR Imaging Market Growth Through Translational Research, Sustainability, and Advanced Healthcare Investments.
Even NIR imaging systems for oncology and research centres are included in strengthening healthcare investments undertaken by Germany, France, the UK, and many other European countries. The European does not leave out innovations in reagents and hybrid devices, but focuses on the market's commitment to standardised imaging quality and sustainability as a means of positioning itself as the leading region in translational research applications.
Asia-Pacific region shows the highest increase due to healthcare expansion and the rising number of cancer patients.
Among the countries making up this region are China and India. These two countries largely dominate the expansion of the region owing to their large population and increasing number of patients looking for advanced technologies in surgery. Research-led innovations contribute significantly from Japan and South Korea, while enhancing adoption in oncology-focused hospitals in Australia. Increased government investments in cancer care and biotechnology will also exponential market growth.
LAMEA NIR Imaging Market Growth Accelerates Through Rising Healthcare Expenditure and Oncology Investments.
Investments in oncology diagnostics are rising in Latin American countries like Brazil and Argentina, while those in the Middle East, especially Saudi Arabia and the UAE, are developing world-class healthcare infrastructure based on NIR imaging. Africa is still in its nascent stages, but it has potential, as awareness of minimally invasive surgery and preclinical research expands.
How Can Stakeholders Benefit from the Near Infrared Imaging Report?
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Questions
The devices segment currently dominates the market. This is primarily due to the essential role these systems play in intraoperative guidance and diagnostic accuracy. Fluorescence-enabled imaging devices are increasingly adopted in hospitals for oncological interventions, particularly for the precise identification of tumor margins.
Reagents are experiencing rapid growth because of the intensification of drug validation and translational research by pharmaceutical companies and research institutions. Advanced NIR probes allow for the visualization of biological processes and the assessment of drug efficacy in both preclinical and clinical settings.
The surge in oncology procedures is the primary driver. Surgeons utilize NIR fluorescence guidance to confirm complete tumor resection while minimizing damage to healthy tissues. Additionally, the rise of minimally invasive surgeries and the demand for early diagnostics are significantly fueling market uptake.
Precision medicine requires advanced imaging platforms to verify targeted drug delivery and provide real-time visualization of molecular pathways. NIR imaging stands at the forefront of this evolution, offering the molecular-level insights necessary for personalized treatment plans and translational oncology.
The emergence of hybrid imaging systems—combining NIR with other modalities like MRI and PET—is a major trend. These systems provide multiparametric diagnostic insights, opening new avenues for commercialization and expanding the use of NIR beyond oncology into fields like neuroscience and cardiovascular research.
North America currently leads the market due to its advanced oncology infrastructure and strong regulatory support (particularly from the FDA). However, the Asia-Pacific region is expected to show the highest growth rate, driven by expanding healthcare infrastructure in China and India and a rising volume of cancer patients.
The primary obstacles include high capital expenditure requirements for equipment and specialized training, which can limit adoption in smaller hospitals or emerging economies. Additionally, manufacturers face high compliance costs due to stringent regulatory frameworks in Europe and North America.
The market features several prominent players, including Stryker Corporation, Olympus Corporation, Karl Storz SE & Co. KG, PerkinElmer Inc., Hamamatsu Photonics K.K., Leica Microsystems, Quest Medical Imaging, Medtronic plc, Shimadzu Corporation, and LI-COR Biosciences.
Biotechnology and pharmaceutical companies are increasingly using NIR imaging for non-invasive, reproducible visualization of therapeutic efficacy in small-animal studies. This demand for laboratory-grade imaging platforms and reagents helps validate drug pipelines, creating lucrative opportunities for device manufacturers and reagent developers.
